Thanks for emailing that article!
David J. Calkins, PhD, a Principal Investigator in the Catalyst For a Cure funded by Glaucoma Research Foundation, has received the very prestigious Rudin prize for the best published paper in glaucoma research last year.
The New York Academy of Medicine (NYAM) has awarded the 2011 Lewis Rudin Glaucoma Prize to David J. Calkins, PhD, Vice-Chairman and Director of Research, Vanderbilt Eye Institute, Associate Professor of Ophthalmology and Visual Sciences, and Associate Professor of Neuroscience and Psychology, also at Vanderbilt University.
The Rudin Glaucoma Prize recognizes the most significant scholarly article on glaucoma published in a peer-reviewed journal in the prior calendar year. Recipients are nominated by their peers, and a winner is chosen by The New York Academy of Medicine’s Lewis Rudin Prize Selection Committee and approved by the NYAM Board of Trustees. The prize was established by Lewis and Jack Rudin, New York builders and philanthropists who recognized the importance of rewarding superior research on glaucoma. Since its inception in 1995, the committee has recognized the outstanding contributions of physicians and scientists working on the challenges of glaucoma and has become a highly respected and acknowledged award.
Dr. David Abramson, Chair of the Lewis Rudin Prize Selection Committee, focused on the importance of Dr. Calkins’ insightful research and his perseverance in helping to foster greater understanding of glaucoma, a disease of the eye that affects an estimated four million Americans each year. It is also the second leading cause of blindness in the world, according to the World Health Organization.
“Dr. Calkins’ work helps to define the scope and impact of this often misunderstood but treatable disease of the eye,” Dr. Abramson said. “The prestigious Rudin Prize honors his critical work and will lead the way to future research regarding the diagnosis and treatment of glaucoma.”
“Dr. Calkins’ work has clarified how and why the delicate nerves in the eye deteriorate in glaucoma and emphasized that loss of vision is more complicated than simply the level of pressure in the eye,” Dr. Abramson said. “The prestigious Rudin Prize honors his critical work and will lead the way to future research and novel therapies to prevent loss of vision in glaucoma.”
For Dr. Calkins, the award represents not only a culmination of his work in Glaucoma but general national recognition of this debilitating disease and its effect on the progression of research and work toward a cure as a result of the Rudin Prize.
“I feel honored to receive this prestigious award and would like to express my sincere thanks to the Academy and to the Rudin family,” Dr. Calkins said. “It is my hope that awards such as this will draw public attention to glaucoma as an age-related neurodegenerative disorder and speed the push for new neural-based treatments.”
Last reviewed on December 23, 2011